Polymerase chain reaction inhibition assay documenting the amotosalen‐based photochemical pathogen inactivation process of platelet concentrates

BACKGROUND: The INTERCEPT Blood System (Baxter Healthcare Corp.) for platelets (PLTs) uses amotosalen‐HCl (S‐59) in conjunction with ultraviolet A (UVA) light to inactivate contaminating pathogens by modifying the nucleic acids of pathogens. The success of this photochemical treatment (PCT) process can be documented indirectly with a high‐performance liquid chromatography assay measuring the photodegradation of amotosalen and measurement of the UVA light dose delivered by the illumination system.

[1]  J. Cazenave,et al.  Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set , 2005, Transfusion.

[2]  Shamkant B. Navathe,et al.  MITOMAP: a human mitochondrial genome database—2004 update , 2004, Nucleic Acids Res..

[3]  B. Molini,et al.  Photochemical treatment of platelet concentrates with amotosalen and long‐wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria , 2004, Transfusion.

[4]  J. Fridey,et al.  Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. , 2004, Blood.

[5]  H. Klüter,et al.  Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets , 2004, Vox sanguinis.

[6]  S. Wollowitz.  Targeting DNA and RNA in Pathogens: Mode of Action of Amotosalen HCl , 2004, Transfusion Medicine and Hemotherapy.

[7]  Peter Bugert,et al.  Messenger RNA profiling of human platelets by microarray hybridization , 2003, Thrombosis and Haemostasis.

[8]  R. Benjamin.  Pathogen Inactivation of Labile Blood Products , 2003 .

[9]  P. Ljungman,et al.  Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. , 2003, Blood.

[10]  W. V. Van Voorhis,et al.  Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV , 2003, Antimicrobial Agents and Chemotherapy.

[11]  H. Eichler,et al.  Storage Characteristics of Split Double-Dose Platelet Concentrates Derived from Apheresis and Treated with Amotosalen Hydrochloride and UVA Light for Pathogen Inactivation , 2002, Transfusion Medicine and Hemotherapy.

[12]  S. Wollowitz.  Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. , 2001, Seminars in hematology.

[13]  R. Salamon,et al.  Determinants of transfusion‐associated bacterial contamination: results of the French Bacthem Case‐Control Study , 2001, Transfusion.

[14]  A. Morell.  Pathogen inactivation of labile blood products , 2001, Transfusion medicine.

[15]  L. Corash,et al.  Inactivation of infectious pathogens in labile blood components: meeting the challenge. , 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[16]  D. Rhenen,et al.  Functional Characteristics of S‐59 Photochemically Treated Platelet Concentrates Derived from Buffy Coats , 2000, Vox sanguinis.

[17]  J. Montoya,et al.  [Diseases of mitochondrial DNA]. , 2000, Revista de neurologia.

[18]  L. Corash,et al.  Photochemical Inactivation of Bacteria and HIV in Buffy‐Coat‐Derived Platelet Concentrates under Conditions That Preserve in vitro Platelet Function , 2000, Vox sanguinis.

[19]  D. Turnbull,et al.  Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA , 1999, Nature Genetics.

[20]  L. Corash,et al.  Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. , 1998, Blood.

[21]  L. Corash,et al.  Photochemical Treatment of Platelet Concentrates with a Novel Psoralen and UVA to Enhance the Safety of Platelet Transfusionsa , 1998, Transfusion Medicine and Hemotherapy.

[22]  J. Hearst,et al.  Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long‐wavelength ultraviolet light , 1997, Transfusion.

[23]  D. Bogenhagen,et al.  Action of Mitochondrial DNA Polymerase at Sites of Base Loss or Oxidative Damage (*) , 1995, The Journal of Biological Chemistry.

[24]  H. Blöcker,et al.  Predicting DNA duplex stability from the base sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Bachellerie,et al.  Identification of the modified nucleotides produced by covalent photoaddition of hydroxymethyltrimethylpsoralen to RNA. , 1981, Nucleic acids research.

[26]  M. Fukami,et al.  Energy metabolism of blood platelets. I. Isolation and properties of platelet mitochondria. , 1972, Archives of biochemistry and biophysics.

[27]  R. Goodrich.  The use of riboflavin for the inactivation of pathogens in blood products. , 2000, Vox sanguinis.

[28]  J E Hearst,et al.  Psoralens as photoactive probes of nucleic acid structure and function: organic chemistry, photochemistry, and biochemistry. , 1985, Annual review of biochemistry.

[29]  W. Luppold,et al.  The Residue Determinant , 2004, math/0406268.